Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Status Recruiting

Clinical Trial Summary

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza or SARS-CoV2 vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize virus-specific plasmablasts and memory B cells after vaccination in patients with lymphoma receiving active treatment or in follow up observation. II. To investigate the longevity of viral-specific humoral immunity to influenza virus in patients with lymphoma receiving active treatment or in follow up observation. III. To assess the timing and strength of the peak immune response to vaccination. IV. To assess the effect of different lymphomas and treatment modalities in the immune response to vaccination. OUTLINE: Patients receive seasonal inactivated influenza vaccine intramuscularly (IM) at day 0. After completion of study treatment, patients are followed up at days 7, 28, 90, 180, and 365. ;

Study Design

Related Conditions & MeSH terms

Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Mantle-Cell
Lymphoma, T-Cell
Mantle Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Clinical Trial Details

NCT number	NCT03501576
Study type	Observational
Source	Emory University
Contact	Andres Chang, MD, PhD
Phone	404-778-3942
Email	andres.chang@emory.edu
Status	Recruiting
Phase
Start date	April 6, 2018
Completion date	October 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Completed	`NCT02057185` - Occupational Status and Hematological Disease
Active, not recruiting	`NCT04240704` - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL	Phase 1
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Active, not recruiting	`NCT03280160` - Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab	Phase 2
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Completed	`NCT00038025` - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies	Phase 2
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Terminated	`NCT02231853` - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections	Phase 1
Recruiting	`NCT05417165` - Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia	Phase 2
Recruiting	`NCT04028531` - Understanding Chronic Lymphocytic Leukemia
Completed	`NCT00001637` - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults	Phase 2
Completed	`NCT02910583` - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)	Phase 2
Completed	`NCT01527045` - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Phase 2
Recruiting	`NCT04679012` - Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	Phase 2
Recruiting	`NCT05405309` - RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia	Phase 1/Phase 2
Active, not recruiting	`NCT05023980` - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Phase 3
Recruiting	`NCT04553692` - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers	Phase 1
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer